Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serine/Glycine-Restricted Diet + Chemoradiotherapy in Rectal Cancer
NCT07912463Phase 2Not yet recruiting
- Sponsor
- Xuelei Ma
- Start
- Nov 2026
- Primary completion
- Nov 2027
01
Overview
Phase 2, randomised, open-label trial in rectal cancer (2 arms), sponsored by Xuelei Ma. Primary endpoint: Complete Response Rate at 24 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07912463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07912463.